Please enable Javascript
Sangeetha Venugopal, MD
Articles by Sangeetha Venugopal, MD
Covering MDS Updates at SOHO 2024 With Dr. Venugopal
Sangeetha Venugopal, MD
The HemOnc Pulse
|
November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Listen Now
How Are Erythropoiesis-Stimulating Agents Used in MDS Care Today?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
July 2, 2024
The expert panel discusses current issues in the use of ESAs within MDS management.
View More
How Is Luspatercept Being Used in Lower-Risk MDS Management?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
July 1, 2024
In a roundtable discussion, an expert panel discussed how approval of luspatercept has affected frontline MDS treatment.
View More
How Do Clinicians Navigate the Two MDS Classification Systems?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
June 21, 2024
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
View More
How Do Clinicians Communicate With Patients About Lower-Risk MDS?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
August 29, 2024
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
View More
How Is Molecular Testing Used in MDS Risk Stratification?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
June 17, 2024
The expert panel discusses molecular testing's current place in MDS evaluation and treatment decisions.
View More
How Is MDS Classification, Prognosis Changing?
Amer Zeidan, MBBS, MHS
The HemOnc Pulse Live
|
June 13, 2024
In a roundtable discussion, an expert panel describes recent trends in the classification and prognosis of MDS in the clinic.
View More
'The HemOnc Pulse' Live: What Research is Needed in CML?
Sangeetha Venugopal, MD
Chronic Myeloid Leukemia
|
June 7, 2024
Sangeetha Venugopal, MD, engages outstanding issues in chronic myeloid leukemia treatment research.
View More
‘The HemOnc Pulse’ Live 2024: Unanswered Questions in CML Treatment
Elias Jabbour, MD
The HemOnc Pulse Live
|
May 21, 2024
The panel mainly discussed frontline tyrosine kinase inhibitors for the treatment of chronic phase CML.
Listen Now
Unanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in Chicago
Chadi Nabhan, MD, MBA, FACP
Myelodysplastic Syndromes
|
May 13, 2024
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
Listen Now
Dr. Venugopal Offers Her Thoughts on the Latest MDS News From ASH 2023
Chadi Nabhan, MD, MBA, FACP
The HemOnc Pulse
|
January 17, 2024
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
Listen Now
How Will Molecular Markers Be Used in MDS Risk Stratification?
Guillermo Garcia-Manero, MD
Video Insights
|
January 12, 2024
The panel discusses forward-looking thoughts for the treatment of low-risk myelodysplastic syndromes.
View More
Can Early Transplant Be Used for Patients with Low-Risk MDS?
Guillermo Garcia-Manero, MD
Video Insights
|
December 18, 2023
The panel talks about the use of transplant for patients with low-risk myelodysplastic syndromes.
View More
Panel Discusses New Data on Emerging Therapies in MDS: Imetelstat, KER-050, Plus More
Guillermo Garcia-Manero, MD
Video Insights
|
January 4, 2024
The panel discusses other treatments undergoing research for MDS, including imetelstat and KER-050.
View More
Real-World Quality of Life, Patient Experience Associated with Luspatercept
Guillermo Garcia-Manero, MD
Video Insights
|
December 18, 2023
The panel shared their thoughts on real-world data of luspatercept presented at ASH 2023.
View More
Panel Shares Thoughts on Luspatercept for MDS and Future Research Needs for This Therapy
Guillermo Garcia-Manero, MD
Video Insights
|
December 18, 2023
The panel addresses continued MDS research needs.
View More
Mutational Status, Comorbidities and MDS Treatment Selection
Guillermo Garcia-Manero, MD
Video Insights
|
December 18, 2023
The panel discusses appropriate treatment selection based on patient mutation status and comorbidities.
View More
Panel Reacts to Full Analysis of the COMMANDS Trial of Luspatercept for MDS
Guillermo Garcia-Manero, MD
Video Insights
|
December 18, 2023
The panel shares their thoughts on the full analysis of the COMMANDS study.
View More
What Are the Treatment Options for Patients with Low-Risk MDS?
Guillermo Garcia-Manero, MD
Video Insights
|
January 4, 2024
The panel discussed the current slate of treatment options for patients with low-risk MDS.
View More
Dr. Venugopal Highlights Myelofibrosis Research at ASH 2023
Sangeetha Venugopal, MD
Myelofibrosis
|
March 4, 2024
Venugopal highlights myelofibrosis research at ASH 2023.
View More
Load More